Brinkals5015

Conclusions A. kalrae keratitis is an exceptionally rare clinical entity that poses significant therapeutic challenges. MALDI-TOF-MS serves as a useful diagnostic technique in identifying this rare organism. Although the literature suggested that A. kalrae keratitis may sometimes be controlled with antifungal medical treatment alone, this approach was proven to be futile in our immunocompromised patient with pre-existing neurotrophic keratopathy, suggesting that early surgical intervention such as therapeutic keratoplasty may be required in these cases.Objectives To assess publications examining the occurrence, composition, and clinical significance of a microbiome at the ocular surface. Methods MEDLINE, EMBASE, and Google Scholar were searched. Reference lists of included articles were also searched for relevant citations. All publications up to June 1, 2019, were analyzed. Results Eleven articles and 1 abstract were included, analyzing 661 patients. Articles generally report bacteria to the genus level. The presence of DNA associated with diverse bacterial species was reported including pathogenic species, such as Pseudomonas and Neisseria. Bacterial DNA that makes up the microbiome, such as Acinetobacter, Actinomyces, Aquabacterium, Bradyrhizobium, Corynebacterium, Sphingomonas, Staphylococcus, and Streptococcus, in other parts of the body was found. The putative ocular microbiome is consistent between right and left eyes and is affected by contact lens use (higher Pseudomonas levels) and blepharitis (higher Staphylococcus levels). Conclusions There is a significant likelihood that there is at least a transitory ocular surface microbiome, with Acinetobacter, Corynebacterium, Propionibacterium, Staphylococcus, and Streptococcus detected in at least 7 of 11 studies. However, further investigation attempting to control for environmental and methodological contaminants (Aquabacterium and Bradyrhizobium are commonly identified as contaminants in DNA extraction kits) is required. Bacteria, such as Propionibacterium, Staphylococcus, and Streptococcus, capable of causing sight-threatening infections may reside on a healthy ocular surface. With greater understanding, we can establish whether elements of the ocular surface microbiome are harmful or protective (despite their small quantities); furthermore, new therapeutic agents can be identified to treat and prevent ocular surface infection and inflammation.Purpose To compare corneal endothelium parameters taken by two common noncontact specular microscopes in healthy subjects. Methods Healthy participants visiting the outpatient eye clinic at the Rabin Medical Center, Petah Tikva, Israel, were recruited prospectively. All participants underwent three consecutive corneal endothelial cell photographs with both the Konan-Noncon Robo SP-6000 and the Tomey EM-3000 specular microscopes. Endothelial cell density (ECD) was evaluated using the manual center technique in both machines. Bland-Altman graphs were used to assess the agreement between the devices, and intraclass correlation coefficient (ICC) served to assess intraobserver variability for each device. Results Recruited were 49 healthy subjects with a mean age of 48.9±15.6 years, 49 right eyes were included. The mean ECD was comparable between the Tomey EM-3000 and the Konan-Noncon Robo SP-6000 (2,713.2±242.4 vs. 2,700.8±300.5 cells/mm, respectively, P=0.47) with a mean difference of 12.4 cells/mm (0.67%), a mean ECD absolute difference of 93.3 cells/mm, and low 95% limits of agreement of -222.0 to +246.9 cells/mm. A folded empirical distribution function curve showed that all differences fell within 525.4 cells/mm, centered around a median of 13.3 cells/mm. Intraclass correlation coefficient was high for both the Konan-Noncon Robo SP-6000 (0.93, 95% confidence interval [CI] 0.89-0.95) and the Tomey EM-3000 (0.88, 95% CI 0.82-0.93). Conclusions The difference in endothelial cell measurements between the Konan SP-6000 and the Tomey EM-3000 specular microscopes through the center and the L-count analyzing techniques, respectively, is clinically small and not statistically significant. Nevertheless, caution should be taken when used interchangeably because ECD difference between the two machines can be as high as 525.4 cells/mm.Purpose To evaluate the effect of a single subconjunctival aflibercept injection on formed corneal neovascularization. Methods A prospective clinical trial, conducted at a single tertiary medical center. Included were consecutive patients with corneal pathologies complicated by corneal neovascularization, who were candidates for anti-vascular endothelial growth factor treatment at the discretion of a cornea specialist. A single subconjunctival injection of 0.08 mL of Aflibercept (Eylea 25 mg/mL) was administered near the limbus in proximity to the areas of maximal pathological neovascularization. Follow-up visits were scheduled on days 7, 30, 60, and 90 following injection. Best-corrected visual acuity (BCVA), intraocular pressure, slitlamp examination, digital cornea photography, specular microscopy, and anterior-segment optical coherence tomography were documented at each visit. The images were graded by a masked observer for density, extent, and centricity of corneal vascularization. Results Six eyes of six patients were analyzed. No clinically significant ocular or systemic adverse events were documented. No change was noted in extent, density, or centricity of corneal blood vessels at seven, 30, and 90 days after injection (P>0.1 for all time point comparisons, Friedman test). Best-corrected visual acuity fluctuated insignificantly in 5/6 patients during follow-up time, and objective but not subjective improvement of BCVA was noted in one patient with no concurrent change of neovascularization. The recruitment has therefore halted prematurely. Conclusions A single subconjunctival aflibercept injection seems to be well tolerated. However, it is ineffective for regressing formed corneal neovascularization.Objective To compare the efficacies of 0.02% atropine eye drops and orthokeratology to control axial length (AL) elongation in children with myopia. Methods In this historical control study, 247 children with myopia whose administration of 0.02% atropine (n=142) or underwent orthokeratology from an earlier study (n=105, control group) were enrolled. Data on AL and other baseline parameters were recorded at baseline and after 1 and 2 years of treatment. Results The mean changes in AL in the first and second years of treatment were 0.30±0.21 and 0.28±0.20 mm, respectively, in the 0.02% atropine group and 0.16±0.20 and 0.20±0.16 mm, respectively, in the orthokeratology group. Axial length elongations after 2 years of treatment were 0.58±0.35 and 0.36±0.30 mm (P=0.007) in the 0.02% atropine and orthokeratology groups, respectively. Multivariate regression analyses showed that the AL elongation was significantly faster in the 0.02% atropine group than in the orthokeratology group (β=0.18, P=0.009). In multivariate regression analyses, younger age and shorter baseline AL were associated with a rapid AL elongation in the 0.02% atropine group (βage=-0.04, P=0.01; βAL=-0.17, P=0.03), while younger age, lower baseline spherical equivalent refractive error (SER), and shorter baseline AL were associated with a greater increase in AL in the orthokeratology group (βage=-0.03, P=0.04; βSER=0.06, P=0.03; βAL=-0.11, P=0.009). Faster AL elongation was found in the 0.02% atropine group compared with the orthokeratology group at higher baseline SER (P=0.04, interaction test). Conclusion Within the limits of this study design, orthokeratology seems to be a better method for controlling AL elongation compared with administration of 0.02% atropine in children with higher myopia over a treatment period of 2 years.Purpose To investigate the effects of a single dose of brimonidine 0.15% on anterior segment morphology, pupil characteristics, and choroidal blood flow in treated and untreated eyes of healthy subjects and to compare the results obtained with those in another healthy volunteer group. Methods Participants were classified as study and control groups. The eyes in the study group were randomized. Only one eye received one drop of brimonidine (treated eyes), and the contralateral eye received single dose of sodium hyaluronate (untreated eyes). In addition, only right eyes of control subjects, who had single dose of sodium hyaluronate to both eyes, were analyzed (control eyes). Anterior segment parameters including central corneal thickness (CCT), aqueous depth, anterior chamber volume, iridocorneal angle (ICA), horizontal anterior chamber diameter, and pupil measurements including scotopic, mesopic, photopic, and dynamic pupil diameters (PDs) were performed with Sirius Scheimpflug camera. learn more Choroidal thickness (CT) measurements were taken with optical coherence tomography. These measurements were taken at baseline and repeated 1 hour after the dosing. Results Only the treated eyes had significantly thicker CCT and wider ICA values after instillation of brimonidine. Static and dynamic PD values of treated eyes and even untreated eyes significantly decreased after brimonidine. However, brimonidine has no significant effect on CT measurements. Conclusion A single dose of brimonidine causes thickening in CCT and widening in ICA values in treated eyes. In addition, it has significant effect to decrease the scotopic, mesopic, photopic, and dynamic PD values in treated and even contralateral eyes while has no effect on choroidal blood flow.Objectives To investigate the prevalence of and risk factors for Demodex mite infestation of the eyelashes in Chinese children. Methods A total of 1,575 children were surveyed from June 2017 to January 2019 and stratified into two age groups 3 to 6 and 7 to 14 years. All subjects underwent routine eye examination and lash epilation for Demodex mite identification and counting using microscopy. Demographic data and lifestyle habits were also recorded. Results Demodex mites were detected in 189 of 1,575 (12.0%) children, including Demodex folliculorum (D. folliculorum) in 180 (11.4%), Demodex brevis (D. brevis) in 11 (0.7%), and both mites in 2 (0.1%). The median number of D. folliculorum mites was 1 (interquartile range [IQR], 1-2) and that of D. brevis was 1 (IQR, 1-1). Children with Demodex infestation did not exhibit more ocular discomfort than those without (21.2% vs. 23.1%; P=0.56). However, lash abnormalities, including trichiasis, cylindrical dandruff, or scaly discharge at the lash root, were more prevalent in children with Demodex infestation (24.9% vs. 12.8%; P less then 0.001) and in the 7 to 14-year subgroup (33.7% vs. 12.8%; P less then 0.001). Multiple logistic regression revealed that autumn-winter was associated with a higher detection rate of Demodex infestation (all P less then 0.05). In the 3-6-year subgroup, children residing in rural regions exhibited a higher prevalence of Demodex infestation (P=0.03). Conclusions Ocular Demodex infestation, with a low Demodex mite count, was found in healthy Chinese children aged 3 to 14 years.Objective To assess the rate of erroneous or expired (invalid) contact lens prescriptions submitted for passive verification at two practice sites in Cleveland, OH. Methods Passive verification facsimile (FAX) requests were collected from office staff at a county hospital (MetroHealth [MH]), and at a private ophthalmology group office (University Ophthalmology Associates [UOA]) in Cleveland, Ohio, from January 2013 to January 2018. Results A total of 415 verification requests were evaluated (339 MH, 75 UOA), 28.2% (104 MH, 13 UOA) were expired, 11.8% (48 MH, one UOA) were not under the care of the doctor to whom the request was directed, 8.9% (32 MH, 5 UOA) were incorrect, and 3.9% (16 MH, 0 UOA) did not complete fitting. The total rate of invalid prescriptions was 52.8% (200 MH, 19 UOA). Conclusions There is a high rate of invalid prescriptions presented for passive verification. Although the majority of prescriptions are simply expired, there is a fraction of prescriptions that contain incorrect specification of lens parameters or no record of prescription by that doctor.